Ishara Investments LP Takes Position in Genmab A/S Sponsored ADR $GMAB

Posted by Stanley Muller on Jun 18th, 2026

Ishara Investments LP acquired a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 70,000 shares of the company’s stock, valued at approximately $2,156,000. Genmab A/S accounts for about 2.5% of Ishara Investments LP’s investment portfolio, making the stock its 13th largest position.

A number of other hedge funds also recently made changes to their positions in GMAB. Paradigm Biocapital Advisors LP purchased a new stake in shares of Genmab A/S during the third quarter valued at approximately $117,063,000. Orbis Allan Gray Ltd raised its stake in shares of Genmab A/S by 30.2% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after purchasing an additional 3,340,456 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Genmab A/S by 36.6% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the period. Pictet Asset Management Holding SA bought a new stake in shares of Genmab A/S in the fourth quarter worth $33,835,000. Finally, Perpetual Ltd bought a new stake in shares of Genmab A/S in the fourth quarter worth $25,478,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Up 2.6%

Shares of NASDAQ:GMAB opened at $25.39 on Thursday. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The company has a fifty day simple moving average of $26.60 and a 200 day simple moving average of $29.08. The firm has a market cap of $15.83 billion, a PE ratio of 19.23, a price-to-earnings-growth ratio of 1.47 and a beta of 0.85. Genmab A/S Sponsored ADR has a 12-month low of $20.23 and a 12-month high of $35.43.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Guggenheim dropped their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Truist Financial assumed coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target for the company. Weiss Ratings lowered shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. Wells Fargo & Company assumed coverage on shares of Genmab A/S in a research note on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price target for the company. Finally, HC Wainwright dropped their price target on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.93.

Read Our Latest Research Report on GMAB

Genmab A/S Profile

(Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.